#### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

# **Listing of Claims:**

- 1. (Currently Amended) A method for identifying a ligand of NPC1L1 comprising:
- (a) contacting human NPC1L1 with a candidate compound and a detectably labeled substituted 2-azetidinone glucuronide compound selected from the group consisting of compound 1, compound 2, compound 8 and a compound of Formula Ha,

# and a compound of Formula IIa

wherein,

(i)  $R^9$  is selected from the group consisting of  $-C \equiv C - CH_2 - NR^{10}R^{11}$  wherein  $R^{11}$  is selected from the group consisting of -H,  $-C_{1-3}$ alkyl,  $-C(O) - C_{1-3}$ alkyl,  $-C(O) - NR^{10}R^{10}$ ,  $-SO_2 - C_{1-3}$ alkyl and  $-SO_2$ -phenyl;  $[[or]] - C \equiv C - C(O)NR^{10} - SO_2 - C_{1-3}$ alkyl;  $-C \equiv C - C(O)NR^{10} - SO_2$ -phenyl;  $-(CH_2)_3 - NR^{10} - SO_2 - C_{1-3}$ alkyl; and  $-(CH_2)_3 - NR^{10} - SO_2$ -phenyl;

(ii)  $R^9$  is selected from the group consisting of C=C  $CH_2$   $NR^{10}R^{11}$ , C=C  $C(O)NR^{10}R^{11}$ ,  $(CH_2)_3$   $NR^{10}$   $SO_2$   $C_{1,3}$  alkyl and  $(CH_2)_3$   $NR^{10}$   $SO_2$  phenyl, wherein  $R^{11}$  is selected from  $H_1$ ,  $C_{1,3}$  alkyl, C(O)  $C_{1,3}$  alkyl, C(O)  $NR^{10}R^{10}$ ,  $SO_2$   $C_{1,3}$  alkyl and  $SO_2$  phenyl;

 $R^{10}$  is independently selected at each occurrence from -H and -C<sub>1-3</sub>alkyl; and  $R^{12}$  is selected from

# (b) measuring the amount of detectably labeled substituted 2-azetidinone glucuronide compound that is bound to NPC1L1, and determining whether said candidate compound binds to human NPC1L1;

wherein binding of said candidate compound to human NPC1L1 modulates <u>decreases</u> binding of said detectably labeled substituted 2-azetidinone glucuronide to human NPC1L1, and wherein said modulation <u>and</u> indicates that the candidate compound is a ligand that binds to of human NPC1L1.

# 2-6. (Cancelled)

- 7. (**Previously Presented**) The method of claim 1, wherein the substituted 2-azetidinone-glucuronide comprises a detectable label from the group consisting of <sup>3</sup>H, <sup>35</sup>S and <sup>125</sup>I.
- 8. (**Previously Presented**)The method of claim 7, wherein the detectable label is substituted 2-azetidinone-glucuronide is a compound of Formula IIa.
- 9. (**Previously Presented**) The method of claim 8, wherein the substituted 2-azetidinone-glucuronide is a compound of Formula II<u>a</u>, wherein  $R^9$  is selected from the group consisting of  $-C \equiv C CH_2 NR^{10}R^{11}$ ,  $-C \equiv C C(O)NR^{10}R^{11}$ ,  $-(CH_2)_3 NR^{10} SO_2 C_{1-3}$  alkyl and  $-(CH_2)_3 NR^{10} SO_2$ -phenyl, and  $R^{11}$  is selected from  $-SO_2 C_{1-3}$  alkyl and  $-SO_2$ -phenyl.
- 10. (**Previously Presented**) The method of claim 9, wherein the substituted 2-azetidinone-glucuronide of Formula IIa is labeled with <sup>35</sup>S.

# 11-20. (**Cancelled**)

21. (Previously Presented) The method of claim 10 wherein  $R^9$  is  $-C \equiv C - CH_2 - NR^{10}R^{11}$ .

22. (**Previously Presented**) The method of claim 1 wherein the detectably labeled substituted 2-azetidinone glucuronide is <sup>35</sup>S-labeled compound 2

23. (Previously Presented) The method of claim 1 wherein R<sup>12</sup> is

- 24. (Currently Amended) The method of claim 1 wherein the detectably labeled substituted 2-azetidinone glucuronide is selected from the group consisting of compound 1, compound 7 and compound 8.
- 25. (**Previously Presented**) The method of claim 24 wherein the detectably labeled substituted 2-azetidinone glucuronide comprises a detectable label selected from the group consisting of <sup>3</sup>H and <sup>125</sup>I.